Vectors allowing hydrophilic compounds to gain access to the cell interior are needed to reach new therapeutic targets. Transduction peptides have opened the way to this, but their chemical mimics may be of even greater interest.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The P42 peptide and Peptide-based therapies for Huntington’s disease
Orphanet Journal of Rare Diseases Open Access 17 March 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Katie Ris
References
Joliot, A. & Prochiantz, A. Nat. Cell. Biol. 6, 189–196 (2004).
Wadia, J.S., Stan, R.V. & Dowdy, S.F. Nat. Med. 10, 310–315 (2004).
Rothbard, J.B. et al. J. Med. Chem. 45, 3612–3618 (2002).
Mae, M. & Langel, U. Curr. Opin. Pharmacol. 6, 509–514 (2006).
Okuyama, M. et al. Nat. Methods 4, 153–159 (2007).
Prochiantz, A. & Joliot, A. Nat. Rev. Mol. Cell. Biol. 4, 814–819 (2003).
Derossi, D., Chassaing, G. & Prochiantz, A. Trends Cell. Biol. 8, 84–87 (1998).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Prochiantz, A. For protein transduction, chemistry can win over biology. Nat Methods 4, 119–120 (2007). https://doi.org/10.1038/nmeth0207-119
Issue Date:
DOI: https://doi.org/10.1038/nmeth0207-119
This article is cited by
-
The P42 peptide and Peptide-based therapies for Huntington’s disease
Orphanet Journal of Rare Diseases (2016)
